Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Scotia Dynamic U.S. Growth Fund Class I (DWUGX)

Net Asset Value
1 Day
Overall Morningstar Rating
Large growth
Style or Category
No Load
Sales Expenses
Expense Ratio
Morningstar Risk Rating™
Investment Objective The investment seeks long-term capital appreciation. The fund invests normally at least 80% of its assets in equity securities of U.S. companies chosen according to a growth oriented investment approach. It may invest in companies of any size, including small and mid capitalization companies, in order to achieve its objective. The fund may from time to time have significant exposure in one or more sectors of the economy, especially the more growth-oriented sectors, such as the information technology, consumer discretionary and health care sectors. It is non-diversified.


1 month+0.07% 3 years+14.53%
3 months-1.99% 5 years+16.40%
1 year+15.63% Since inception+23.96%
Data through --

Peer Comparisonvs. Large growth

Performance 5-yr return+16.40%+16.96%
Expense ratio1.13%1.20%
Risk 5 year sharpe ratio1.051.15
Net assets$71.4M$2.7B
Average market cap$17.5B$76.7B
Average P/E44.520.6
Portfolio turnover----

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyScotiaFunds
Fund manager & tenureNoah Blackstein / 6 Years
Minimal initial investment$25,000.00
Minimum IRA investment$25,000.00


U.S. stock92.32%
International stock1.90%
Fixed income0.00%
Top 5 Sectors
Portfolio weighting
Consumer service 27.11%
Telecommunication 17.84%
Hardware 15.87%
Healthcare 14.34%
Consumer goods 5.13%
Top 10 Holdings
Portfolio weighting
DATA Tableau Software Inc6.85%
PANW Palo Alto Networks Inc5.75%
CRM Salesforce.com5.68%
FB Facebook5.23%
ULTA Ulta Salon Cosmetics and Fragrance Inc5.13%
UA Under Armour4.99%
ORLY O'Reilly Automotive Inc4.76%
ILMN Illumina Inc4.27%
EXPE Expedia Inc4.27%
REGN Regeneron Pharmaceuticals4.08%

Partner Offers